US company starts clinical trial using stem cells to treat macular degeneration
Advanced Cell Technology Receives FDA Clearance For the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration — FDA Lifts Clinical Hold; Company to Commence a Phase I/II Clinical Trial at Multiple Centers – Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC) announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt’s Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world.